It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

Corporate news

Year

    2018

    Yumanity Therapeutics announces first clinical candidate for the potential treatment of Parkinson’s disease
    Nerina Coppini, 5 September 2018

    First-in-Human Trials Planned for the Fourth Quarter of 2019 IND-Enabling Studies to Be Completed Utilizing Evotec INDiGO Platform

    Evotec and Carna Biosciences collaborate on INDiGO platform
    Nerina Coppini, 8 May 2018

    Evotec leverages INDiGO platform to accelerate the development of Carna's programme CB-1763 through to IND filing IND-filing envisaged for first half of 2019 INDiGO, a key value-driving component of Evotec's EVT Execute business segment, accelerates early drug candidates into the clinic by reducing time from nomination to regulatory submission

    Evotec forms collaboration with Petra Pharma on INDiGO platform
    Nerina Coppini, 11 April 2018

    Petra Pharma Corporation to harness Evotec's INDiGO platform to accelerate its lead programme (Petra-01 for oncology indications) through IND filing Evotec eligible to receive success-based milestones and research funding Evotec's INDiGO, a key value-driving component of its EVT Execute business segment, accelerates early drug candidates into...

    Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic
    Nerina Coppini, 29 March 2018

    INDiGO® is the market leading integrated drug development solution that accelerates drug candidate delivery from candidate selection through to IND submission in typically less than 52 weeks.

    All posts

     

    Other announcements

    Merger

    The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

    Contact us

    Gabriele Hansen

    VP, Corporate Communications & Investor Relations

    T +49 40 560 81 255 F +49 40 560 81 333 vCard

    Katja Werner

    Investor Relations Associate

    T +49 40 560 81 210 F +49 40 560 81 333 vCard